2,3-bis(3'-hydroxybenzyl)butyrolactone has been researched along with triclosan in 1 studies
| Studies (2,3-bis(3'-hydroxybenzyl)butyrolactone) | Trials (2,3-bis(3'-hydroxybenzyl)butyrolactone) | Recent Studies (post-2010) (2,3-bis(3'-hydroxybenzyl)butyrolactone) | Studies (triclosan) | Trials (triclosan) | Recent Studies (post-2010) (triclosan) |
|---|---|---|---|---|---|
| 319 | 32 | 124 | 3,373 | 379 | 1,772 |
| Protein | Taxonomy | 2,3-bis(3'-hydroxybenzyl)butyrolactone (IC50) | triclosan (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 0.585 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Escherichia coli K-12 | 0.4995 | |
| Carbonyl reductase [NADPH] 1 | Homo sapiens (human) | 0.4 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Haemophilus influenzae Rd KW20 | 0.19 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Bacillus subtilis subsp. subtilis str. 168 | 0.5 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 2.8712 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Francisella tularensis subsp. tularensis SCHU S4 | 1.9125 | |
| Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI | Staphylococcus aureus subsp. aureus MRSA252 | 0.4976 | |
| Enoyl-acyl carrier reductase | Toxoplasma gondii | 0.0167 | |
| Enoyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0872 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adgent, MA; Rogan, WJ | 1 |
1 other study(ies) available for 2,3-bis(3'-hydroxybenzyl)butyrolactone and triclosan
| Article | Year |
|---|---|
Triclosan and prescription antibiotic exposures and enterolactone production in adults.
Topics: 4-Butyrolactone; Adult; Anti-Bacterial Agents; Female; Gastrointestinal Microbiome; Humans; Lignans; Male; Middle Aged; Prescription Drugs; Triclosan; Young Adult | 2015 |